M.J. Jimenez-Exposito

436 total citations
13 papers, 318 citations indexed

About

M.J. Jimenez-Exposito is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, M.J. Jimenez-Exposito has authored 13 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 6 papers in Infectious Diseases and 6 papers in Epidemiology. Recurrent topics in M.J. Jimenez-Exposito's work include Hepatitis C virus research (10 papers), HIV/AIDS drug development and treatment (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). M.J. Jimenez-Exposito is often cited by papers focused on Hepatitis C virus research (10 papers), HIV/AIDS drug development and treatment (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). M.J. Jimenez-Exposito collaborates with scholars based in Spain, France and Austria. M.J. Jimenez-Exposito's co-authors include Rafia Bhore, Stanislas Pol, Gregory J. Dore, Alexander Thompson, Stephen Pianko, Peter Angus, Jean–Pierre Bronowicki, Christophe Hézode, Vincent Leroy and Katherine Stuart and has published in prestigious journals such as Hepatology, Clinical Infectious Diseases and Journal of Hepatology.

In The Last Decade

M.J. Jimenez-Exposito

13 papers receiving 309 citations

Peers

M.J. Jimenez-Exposito

EPIDE

HEPAT

RHEUM

Mirella Onofrio Italy

Kian Bichoupan United States

Alison Uriel United Kingdom

Á. Castro Spain

J González Spain

Sherilyn Brinkley United States

Antonio Carlotto Italy

C. Cooper Canada

Ana Arizcorreta Spain

Sheila Tumilty United States

Mirella Onofrio Italy

M.J. Jimenez-Exposito

344 ×1.3

EPIDE

366 ×1.4

HEPAT

90 ×1.0

8 ×0.4

18 ×1.0

RHEUM

Citations per year, relative to M.J. Jimenez-Exposito M.J. Jimenez-Exposito (= 1×) peers Mirella Onofrio

Countries citing papers authored by M.J. Jimenez-Exposito

Since Specialization

Citations

This map shows the geographic impact of M.J. Jimenez-Exposito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.J. Jimenez-Exposito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.J. Jimenez-Exposito more than expected).

Fields of papers citing papers by M.J. Jimenez-Exposito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.J. Jimenez-Exposito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.J. Jimenez-Exposito. The network helps show where M.J. Jimenez-Exposito may publish in the future.

Co-authorship network of co-authors of M.J. Jimenez-Exposito

This figure shows the co-authorship network connecting the top 25 collaborators of M.J. Jimenez-Exposito. A scholar is included among the top collaborators of M.J. Jimenez-Exposito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.J. Jimenez-Exposito. M.J. Jimenez-Exposito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Welzel, Tania M., J. Petersen, Kerstin Herzer, et al.. (2016). Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program. Journal of Hepatology. 64(2). S825–S825. 3 indexed citations

Kowdley, Kris V., P. Angus, Daniel Bernstein, et al.. (2016). All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3+. Journal of Hepatology. 64(2). S789–S790. 4 indexed citations

Hézode, Christophe, Gregory J. Dore, Stephen Pianko, et al.. (2016). Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis. Journal of Hepatology. 64(2). S753–S754. 2 indexed citations

Leroy, Vincent, Peter Angus, Jean–Pierre Bronowicki, et al.. (2016). Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+). Hepatology. 63(5). 1430–1441. 194 indexed citations

Petersen, J., Tania M. Welzel, Kerstin Herzer, et al.. (2016). Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program. Journal of Hepatology. 64(2). S781–S782. 4 indexed citations

Welzel, Tania M., J. Petersen, Michael Gschwantler, et al.. (2015). Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe. Zeitschrift für Gastroenterologie. 53(8). 4 indexed citations

Welzel, Tania M., Kerstin Herzer, Péter Ferenci, et al.. (2015). P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program. Journal of Hepatology. 62. S619–S620. 36 indexed citations

Macı́as, Juan, Karin Neukam, Josep Mallolas, et al.. (2012). Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients. HIV Clinical Trials. 13(2). 61–69. 17 indexed citations

Pineda, Juan A., Karin Neukam, Josep Mallolas, et al.. (2011). Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. Journal of Infection. 64(2). 204–211. 6 indexed citations

10.

Pérez‐Molina, José A., Oscar K. Serrano, Ana Milinkovic, et al.. (2010). Comparison of Antiviral Activity of Regimens Containing Nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue Therapy (The NUCREST Study). HIV Clinical Trials. 11(5). 294–302. 1 indexed citations

11.

Jimenez-Exposito, M.J., Carlos A. Mestres, Xavier Claramonte, et al.. (2006). Mortality and Morbidity in HIV-Infected Patients Undergoing Coronary Artery Bypass Surgery: a Case Control Study. Revista Española de Cardiología (English Edition). 59(3). 276–279. 12 indexed citations

12.

Jimenez-Exposito, M.J., Carlos A. Mestres, Xavier Claramonte, et al.. (2006). Morbimortalidad en pacientes con infección por el virus de la inmunodeficiencia humana que reciben cirugía de revascularización miocárdica: estudio de casos y controles. Revista Española de Cardiología. 59(3). 276–279. 8 indexed citations

13.

Jimenez-Exposito, M.J., Gerard Torres, Natividad Benito, et al.. (2004). Native Valve Endocarditis due toCandida glabrataTreated without Valvular Replacement: A Potential Role for Caspofungin in the Induction and Maintenance Treatment. Clinical Infectious Diseases. 39(7). e70–e73. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact